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Abstract
Purpose To describe the use of ciprofloxacin and flucona-
zole for the treatment of sepsis in European neonatal inten-
sive care units (NICUs) in order to better orient research
aimed at acquiring essential knowledge in this critical area.
Methods The survey consisted of an online questionnaire
for all participating NICUs on treatment schemes employed,
rationales behind drug choices and interest in participation
in research involving the two drugs.
Results A total of 189 level II and III NICUs participated in the
survey, representing 25 countries, with Italy, UK and France
providing the greatest number of centres (54 % of total).
Ciprofloxacin is used in 25 % of NICUs that responded,
although the indications for administering it vary be-
tween centres and the dosage ranges vary considerably,
with 25 % of NICUs giving ≤10 mg/kg/day and another
25 % giving ≥21 mg/kg/day. Factors given as affecting the
decision to use ciprofloxacin are uncertainty about its safety
and pharmacokinetics and level of penetration in the cerebro-
spinal fluid. Among the 70 % of responding units that use
fluconazole to treat fungal infection, 45 % administer 6 mg/kg
unit doses while 33 % administer 12 mg/kg; 41 % of NICUs
use a 24-h interval between administrations while 20 % wait
72 h. Among the responding NICUs, 57 % were willing to
participate in a project on ciprofloxacin and 59 % would
consider participating in a randomized controlled trial evalu-
ating fluconazole versus micafungin.
Conclusions Great variability in therapies exists within and
between countries. Numerous centres are interested in par-
ticipating in research on these drugs, highlighting the need
for further knowledge on sepsis treatment and European
centres’ interest in off-patent medicine research.
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Introduction
Infections in neonates may be caused by bacteria or fungi
and may be responsible for neonatal death or short- and
long-term sequelae [1–3]. In general, data show that the risk
of late-onset sepsis increases with decreasing birth weight
and gestational age and that hospital-acquired infections are
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common among very-low-birth weight infants (VLBW;
<1500 g at birth). There is a lack of safety and efficacy data
on the use of antibiotics and antifungals in preterm
newborns and, consequently, adequate, updated information
on the treatment of sepsis is warranted [4, 5]. Treatment of
these infections is essential but entails increased risks of
death, as with prolonged routine empirical antibiotic thera-
py, and of possible adverse reactions and the emergence of
drug resistance [6–9].
Ciprofloxacin is used to treat sepsis caused by multiple
resistant organisms [10]. It is not considered in current
guidelines for neonatal sepsis, but is increasingly being
used, especially when severe infections are caused by Enter-
obacter spp. resistant to standard treatment and when there
is a major risk of cerebral abscess [11, 12]. Fluconazole, on
the other hand, is an antifungal that is considered by the
Infectious Disease Society of America (IDSA) guidelines to
be a reasonable option for treatment of invasive candidiasis,
a common and often fatal condition in preterm VLBW
infants [13]. There is insufficient data, however, on the
pharmacokinetics, efficacy and safety of these two drugs
in neonates to permit safe and effective use [11, 12, 14–16].
Moreover, the lack of therapeutic knowledge and suitable
formulations for children and the consequent increase in
risks associated with off-label drug use are widely acknowl-
edged and [17] particularly critical in newborns [18].
It is in this context that a European project called Treat
Infections in Neonates (TINN) was set up (www.tinn-pro-
ject.org) under the 7th Framework Programme [18], linking
16 partners from seven EU member states. It will evaluate
the utility and safety of ciprofloxacin and fluconazole be-
cause these two drugs are included in the European Medi-
cines Agency’s priority list of off-patent products with the
highest need for studies in preterm and term neonates [19].
The use of these drugs, administered as formulations adap-
ted to preterm and term neonates, will be assessed in order
to apply for a Paediatric-Use Marketing Authorization and
to establish optimal use of these drugs and guidelines to be
used throughout Europe.
A survey was set up as a preliminary part of the TINN
project to describe the current use of these drugs in neonatal
intensive care units (NICUs) in Europe.
Methods
The survey, in the form of an online questionnaire with a
selection of obligatory items, consisted of four sections
aimed at collecting data on each participating NICU in terms
of: (1) general information, (2) use of ciprofloxacin and
fluconazole, (3) choice to use these drugs or not and the
factors influencing the choice and (4) presence in clinical
research. The items (Appendix 1) were measured on a 5-
point Likert scale (1 0 least important, 5 0 most important).
The questionnaire was partly based on a previous U.S.
survey [20], which was also used in a later study adminis-
tered to individual physicians [21], and has been also used
in the TINN’s survey on the prophylactic use of fluconazole
[22], as was the Likert scale methodology. This latter con-
sisted in, for each drug, grouping respondents into those
who used it and those who did not, and then comparing their
responses after dichotomization. The complete methodology
has already been described in these articles. Categorical
variables were compared by χ2 analysis and the P values
are two-tailed. Data were managed using Microsoft Access
and analysed using SAS ver. 9.12(SAS Institute, Cary, NC).
From December 2009 to May 2010 various methods
were used to contact the greatest number of NICUs in order
to be as representative as possible of the European situation
(27 member states, plus Turkey and Croatia). Individual
researchers, physicians, other healthcare workers and col-
leagues were contacted, and the Internet and bibliographic
databases were searched for additional contacts, including
relevant networks and societies. All contacts were emailed
an invitation letter to contribute to the survey, asking for
participation by a structured staff neonatologist in the NICU
and specifying that all participants would be sent a data
report. In an attempt to avoid a greater participation of
NICUs that use either of the two drugs than of those that
do not, the invitation letter did not mention the drugs under
study. Additional emails were sent to solicit participation
and to complete missing data.
Results
The data set consisted of completed records from 199
NICUs. In order to have a more homogenous sample of
centres, only level II and III NICUs were evaluated. In all,
completed questionnaires from 189 level II and III NICUs
(25 and 164, respectively) were analysed.
Twenty-five European countries were represented by the
data, with the greatest number of participating NICUs locat-
ed in Italy (38 NICUs), UK (36), and France (28), followed
by Sweden (17), Spain (13), Germany (12), Belgium (11),
Finland (5), Austria, Hungary, the Netherlands (3 each),
Poland, Portugal, Slovakia, Estonia, Croatia, Turkey (2
each), and Luxembourg, Greece, Romania, Slovenia, Den-
mark, Czech Republic, Bulgaria, Ireland (1 each). Among
the participating NICUs, 84 % reported >120 annual admis-
sions and 70 % had between 50–200 annual admissions of
newborns at <32 weeks gestational age (22 % had <50 and
8 % had >200). The reported prevalence of fungal infections
was low: in 64 % of NICUs it was <1 % and in 94 % <5 %.
Regarding bacterial sepsis, the majority of NICUs (72 %)
reported a monthly rate of one to ten cases.
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Ciprofloxacin treatment
Most NICUs (89 %) have a standard written protocol
regarding antibiotic treatment in cases of suspected bac-
terial sepsis. Ciprofloxacin, however, is only used in 47
NICUs (25 %). Sweden, with 17 participating NICUs,
stands out because none of its NICUs use the drug.
Ciprofloxacin is most commonly used in cases of
culture-proven bacterial sepsis due to multi-drug resis-
tant organisms that are sensitive to ciprofloxacin (38/47
NICUs). Of these centres, 25 also specified that they
used it as first-line therapy.
Seventeen NICUs reported administering ciprofloxa-
cin in cases of severe sepsis resistant to a first-line
empirical antibiotic therapy that was not ciprofloxacin.
Nine NICUs did not specify the dosage, and the remain-
ing 38 administer ciprofloxacin in dosages that vary
enormously both between countries and between NICUs
at the national level (Table 1), with the most commonly
used regimen being 20 mg/kg/day (42 % of units);
however, 27 % of units administer ≤10 and 19 %
administer≥30 mg/kg/day.
The main concerns expressed by most NICUs were
antibiotic resistance and lack of safety and efficacy data
for ciprofloxacin. However, the NICUs that did not use
the drug were significantly more likely to be concerned
about the scarce information available on the drug’s
safety (p<0.01) and kinetics (p<0.03). Ciprofloxacin
penetration in the cerebrospinal fluid, on the other hand,
was a significant factor in the choice to use the drug
(p≪0.01).
Fluconazole treatment
Of all the participating NICUs, 68 % have a standard written
protocol regarding fluconazole use in treatment, and 70 % of
NICUs administer fluconazole for treatment of systemic
fungal infection. Interestingly, 27 % of the NICUs who
administer fluconazole do not have a standard written pro-
tocol. The dosages used in the different NICUs vary signif-
icantly (Table 2), with wide ranges in the unit doses (45 %
of NICUs administer 6 mg/kg while 33 % administer 12 mg/
kg) and in the interval between administrations (41 % of
NICUs follow a 24-h interval while 19 % wait 72 h). When
transformed into daily doses, the reported data range from 1
to 20 mg/kg/day, with 34 % of NICUs administering ≤4 mg/
kg/day and 49 % administering ≥6 mg/kg/day. Only 16 % of
the NICUs administer 12 mg/kg/day, as recommended in the
IDSA guidelines.
Most NICUs who administer fluconazole (85 %) use the
intravenous (IV) route only, while 15 % use oral±IV. NICUs
that do not administer fluconazole for fungal treatment often
use Liposomal amphotericin B/amphotericin B instead. No
factors resulted significant in terms of the NICUs’ choice to
use the drug or not.
Interest in research participation
Almost two-thirds of NICUs (63 %) belong to a research
network. Numerous centres reported a willingness to partic-
ipate in a TINN project evaluating ciprofloxacin (57 %),
even though many of these centres (73 %) do not normally
use the drug. In general, 85 % of NICUs would be interested
Table 1 Average dose of cipro-
floxacin used in 38 neonatal in-
tensive care units
Data are presented as the number
of neonatal intensive care units
(NICUs). Data from 9 NICUs
that did not specify dosage are
excluded
Country Average dose of ciprofloxacin (mg/kg/day) Total
<10 10 11–15 20 21–25 30 45
France 1 6 1 5 13
Italy 2 3 5
Belgium 1 1 1 3
UK 3 3
Poland 1 1 2
Spain 2 2









Total 4 (11 %) 6 (16 %) 3 (8 %) 16 (42 %) 2 (5 %) 6 (16 %) 1 (3 %) 38
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in participating in a TINN European multicentre project
evaluating medicines in neonates.
Discussion
Ciprofloxacin therapy
The results of this survey reveal a heterogeneous situation
regarding neonatal sepsis in NICUs throughout Europe, not
only concerning drug therapy; for example, the incidence
rates of infection vary between NICUs. These could, how-
ever, be explained by differences in clinical practice, regard-
less of birth weight, gestation and disease severity [23, 24].
The most striking result highlighted by this survey is the
difference in therapeutic responses to infection in preterm
and term neonates in the different NICUs, both between and
within countries. The underlying rationales expressed by the
NICUs for their choices with respect to the use of these two
drugs also vary and reveal uncertainty and a desire for
adequate therapeutic data.
Only one in four NICUs uses ciprofloxacin. One of the
main concerns expressed by respondents was antibiotic
resistance. The use of broad spectrum antibiotics, such as
ciprofloxacin, may in fact increase resistance in the unit and
may lead to complications in later childhood [8]. Lack of
safety and efficacy data in neonates were also issues of
concern. In fact, despite their wide use, antibiotics have
not been broadly compared for safety and efficacy in the
treatment of suspected neonatal sepsis [16, 25]. A retrospec-
tive cohort study of premature babies found no effect on
linear growth due to ciprofloxacin exposure after 12 months
[26]. Furthermore, a recent systematic review [14] con-
firmed the presence of musculoskeletal adverse events in
children, but found that the risk of arthropathy is relatively
low and the condition reversible. Further prospective studies
on ciprofloxacin safety are needed, however, especially in
newborns. Based on this lack of safety and efficacy data, the
TINN project aims to conduct a well-designed study to meet
this need, which is well-perceived on the part of the NICUs.
No guidelines on the use of ciprofloxacin for sepsis were
found. The British national Formulary for Children (BNF-
Table 2 Average dosages of fluconazole used in 126 NICUs
Interval (h): 24 24 24 24 48 48 48 72 72 72 Othera Total
Average unit dose: 3 6 12 20 3 6 12 3 6 12
Country
Austria 2 2
Belgium 2 1 2 2 3 10
Bulgaria 1 1
Croatia 1 1 2
Denmark 1 1
Estonia 1 1
Finland 2 2 4
France 5 2 1 1 4 1 2 1 17
Germany 3 1 2 4 10
Hungary 1 2 3
Ireland 1 1
Italy 7 5 1 2 1 1 17
Netherlands 3 3
Poland 1 1 2
Portugal 1 1 2
Slovakia 1 1 2
Slovenia 1 1
Spain 1 1 4 6
Sweden 1 1 3 2 1 2 4 14
Turkey 1 1 2
UK 1 1 1 1 1 3 1 2 6 3 5 25
Total 1 (1 %) 28 (22 %) 20 (16 %) 2 (2 %) 1 (1 %) 17 (13 %) 12 (10 %) 3 (2 %) 12 (10 %) 9 (7 %) 21 (17 %) 126
Data from 6 NICUs that did not specify dosage are excluded
a Variable dosages, based on child’s condition (took into consideration gestational age, age, birth weight)
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C) [27] recommends other agents for the treatment of neo-
natal bacteraemia and mentions ciprofloxacin for cases of
septicaemia caused by multi-resistant organisms, but it does
not provide dosage recommendations. This lack of guide-
lines is reflected in the data reported in this survey, as
dosage ranges vary greatly, both between and within
countries.
Fluconazole therapy
The use of fluconazole for treatment of fungal sepsis
is common, even though dosages vary markedly. Flu-
conazole is suggested as an option in the treatment of
invasive candidiasis by the IDSA guidelines, at a dos-
age of 12 mg/kg daily [13]. The fact that only 16 %
of the NICUs reported using this dosage highlights the
lack of common, acknowledged guidelines. A measure
of additional importance, with respect to other factors,
was given to the fact that additional efficacy studies in
the perinatal population are needed for this drug. No
factors were significant enough, however, to influence
the NICUs’ decision to use the drug or not. There was
also no correlation between the NICUs’ use of fluco-
nazole for prophylaxis and their use of the drug in
treatment [22].
This survey has some limitations, in particular the repre-
sentativity of the sample. However, as the aim of the study
was to describe the prevailing picture of the use of the two
drugs in NICUs in Europe, the size of the participating
NICUs (even if the actual denominator of those contacted
is unknown) and the countries represented can support the
reported findings.
Conclusions
The survey reveals the presence of a great variability in
the therapies employed by NICUs, both within and
between countries. The differing clinical practices be-
tween NICUs, especially in the treatment schemes
employed for the treatment of fungal and bacterial
infections, need to be addressed at the European level
because they underline a lack of evidence-based guide-
lines harmonizing the different countries [28, 29].
The fact that numerous centres would be interested
in participating in research on these drugs, and in
research evaluating medicines in neonates in general,
demonstrates their desire and recognition of the need
to improve therapeutic knowledge in this vulnerable
population. These results are extremely positive with
respect to TINN’s overall goal because they reveal
fertile ground in Europe for researching and imple-
menting homogeneous, internationally acknowledged
information and guidance on the treatment of two
serious conditions in neonates.
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Appendix 1. Factors taken into consideration
in the decision to use or not to use the two drugs
Rationale for your NICU practice regarding
use of ciprofloxacin
Please indicate the importance each of the following factors
listed below has on your decision to use or not to use
ciprofloxacin in neonates as described above (1: least im-
portant, 5: most important):
a) Incidence of neonatal sepsis due to multi- drug resistant
organisms is/is not high in your NICU
b) Ciprofloxacin has a broad bacterial spectrum
c) Ciprofloxacin has a good penetration in the cerebrospi-
nal fluid
d) Ciprofloxacin is less costly than other antibiotics used
in the same indication
e) Additional efficacy studies of ciprofloxacin in neonatal
bacterial sepsis are needed
f) Uncertainty about safety of the use of ciprofloxacin in
the newborn is great
g) Uncertainty about pharmacokinetics of ciprofloxacin in
the newborn is great
h) Widespread use could lead to increased bacterial
resistance
I) Ciprofloxacin should be reserved only for infections
with multi-drug resistant microorganisms
Rationale for fluconazole treatment in your NICU
Please indicate the importance of the following clinical
factors listed below has on your decision to prescribe em-
piric therapy (10 least important, 50most important):
a) The agent is less costly compared to other available
antifungals
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b) Statement by Pediatric Societies (AAP) supporting the se-
lection of one antifungal for treatment in neonates is needed
c) Uncertainty about pharmacometrics of the other anti-
fungal agents in the newborn is greater than for
fluconazole
d) Uncertainty about safety of the other antifungal agents
in the newborn is greater than for fluconazole
e) Additional studies of efficacy in the perinatal population
are needed for the other antifungal agents
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